Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

RATINGS CHANGES

Amazon (AMZN) was initiated with an overweight rating at Barclays. The company has the best growth potential among top internet names, Barclays said. 

Chemours (CC) was upgraded to buy at Jefferies. $48 price target. TiO2 and fluoropolymers could drive further upside, Jefferies said. 

Capital One (COF) was upgraded to buy from neutral at Nomura. $105 price target. The company's subprime bet should now pay off, Nomura said. 

Dunkin' Brands (DNKN) was downgraded to sell from neutral at Goldman Sachs. $47 price target. The company is trading at a peak valuation and is facing growth headwinds, Goldman said. 

Darden (DRI) was downgraded to neutral from buy at BTIG. The valuation is less attractive, as the stock is trading at 19 times expected 2018 earnings, BTIG said.

Facebook (FB) was initiated with an overweight rating at Barclays. $154 price target. The company is the best pure play on mobile advertising, Barclays said. 

F5 Networks (FFIV) was downgraded to sell from hold at Deutsche Bank. $100 price target. Earnings estimates were also cut, as growth should decelerate into 2018, Deutsche said. 

Alphabet (GOOGL) (GOOG) was initiated with an overweight rating at Barclays. $1,065 price target. The company can generate 20% annual sales and earnings growth for the next few years, Barclays said. 

Morgan Stanley (MS) was upgraded to buy from hold at Deutsche Bank. $47 price target. Stock is down 10%, but the analyst is optimistic about capital markets and an improvement in trading, Deutsche said. 

Nabors Industries (NBR) was downgraded to sell at TheStreet Ratings. You can view the full analysis from the report here: NBR.

Target (TGT) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: TGT.

Twitter (TWTR) was initiated with an underweight rating at Barclays. $14 price target. Revenue growth has turned negative and the stock is trading at 110 times expected 2018 EBITDA, Barclays said. 

Vertex (VRTX) was upgraded to outperform from market perform at BMO Capital. $128 price target. Positive Phase III data suggests that triple combination treatment now has a 65% chance of success, BMO said. 

This article was written by a staff member of TheStreet.

More from Stocks

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Micron Shares Pop After-Hours as Chipmaker Announces $10 Billion Stock Buyback

Micron Shares Pop After-Hours as Chipmaker Announces $10 Billion Stock Buyback

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Dow Leads Major Indices With Triple-Digit Rally

Dow Leads Major Indices With Triple-Digit Rally

Micron CEO: Internet of Things and Data Economy Will Drive Company's Growth

Micron CEO: Internet of Things and Data Economy Will Drive Company's Growth